Omnyx Shutters Doors in Pittsburgh

In the first public news I am aware of since we mentioned in July (see: Changes Coming at Omnyx – Developing Story), the Pittsburgh-Post Gazette reported yesterday that “Omnyx Ends UPMC affiliation, closes Homestead headquarters“. The story reports that “Digital pathology company Omnyx LLC will be folded into GE Healthcare at the end of the month, ending an eight-year partnership with Pittsburgh hospital system giant UPMC to commercialize a nascent technology.”

CEO Andy Chomos was quoted as saying that “regulatory uncertainty” was a “strong contributor” as was “the business was very expensive to maintain”.  This combined with citing “…variable global demand” has resulted in Omnyx’s decision to close operations at their headquarters near downtown Pittsburgh.  A Toronto office and one in New Jersey were closed in 2013 and 2015, respectively.

One of the many exciting developments in the past 7 years has been the level of investment being made by the likes of large global healthcare manufacturers such as Leica, Philips, Roche and Sectra, among others.  GE Healthcare’s investment in this space going back to 2008 appeared to signal further validation that digital pathology was increasingly being recognized as a technology that would become part of routine use in laboratories. The academic and industry collaboration, as I mentioned in July, was particularly exciting for pathologists such as myself as a consumer of the technology.

Certainly the loss of GE Healthcare and the collaboration with UPMC as Omnyx is not positive for the industry. The loss of a “large player” in an emerging industry with a change of business strategy here is not reassuring for the industry at large. Omnyx was the first company in GE’s history to be formed with an academic medical center and represents an aim to accelerate ideas to market through enhanced co-development (see: GE and University of Pittsburgh Medical Center Launch New Business to Digitize and Revolutionize Disease Detection).

That being said, this may speak to GE Healthcare’s general interest and experience in the laboratory market over the past 6 years that has had other issues, including the purchase of Clarient at the end of 2010 for reported $580 million (and perhaps as high as $650 million) which was sold 5 years later to Neogenomics for a reported $275 million. The purchase of Clarient at the time coincided with sharp cuts in reimbursements for technical laboratory services which was a significant portion of Clarient’s business model. It also seemed that Omnyx could not leverage this relationship with Clarient, announcing a collaboration in early 2015 (see: GE Healthcare Building a Stronger Network in the Fight Against Cancer), with the sale of Clarient to Neogenomics coming 7 months later. Perhaps had their investment in a laboratory provider been different that incorporated Omnyx technology, this story may have a different ending.

As we mentioned in July, GE Healthcare confirmed plans were in place to support existing customers and honor contractual commitments.

Proscia Announces Free Massive Dataset Migration Service to Accelerate Transfer of Petabytes of Large-Scale Digital Pathology Image Data to the Cloud

prosciauserProvides free service to address the challenge of securely and rapidly moving petabytes of image data to the cloud

Proscia Inc., the provider of the leading cloud-based platform for digital pathology, announced today a new service to enable rapid migration of large pathology data sets to the Proscia Pathology Cloud platform. The inefficiency in data upload has remained one of the factors limiting adoption of digital pathology. Proscia’s free massive dataset migrator makes the secure, HIPAA-compliant upload of data time, cost, and resource efficient.

Proscia and its customers often deal with very large images or datasets in digital pathology, where upload and migration can be major challenges. Pathology departments looking to adopt digital pathology software often have existing databases of images and corresponding patient data many gigabytes in size. Proscia has become a leader in managing high-volume digital pathology customers with best-in-class upload and migration solutions, as well as a focus on accessibility and security of customer data as a foundational principle. This new product offering enables clients to upload as much as 1 petabyte per week without using client bandwidth, and is provided free-of-charge to existing customers.

“Our team recognizes that some organizations may have doubts about their ability to migrate their existing images and data away from legacy, on-premises storage,” said Coleman Stavish, CTO at Proscia, “The dataset migrator has helped us eliminate that problem for our customers.”

The Proscia Pathology Cloud already implements two other data migration solutions working with its partners at Amazon Web Services and other cloud providers to serve hundreds of users from top institutions with a secure and compliant cloud-based platform for hosting, managing, and analyzing images of tissue and related data, and has recently announced an expansion towards tissue analytics.

More About Proscia
· Access Proscia’s Pathology Cloud
· Request a Demo of Proscia’s software
· Read about Digital Pathology and the Big C’s (That’s “Cancer” and “Cloud”)
· We’re hiring! Reach out to info(at) to learn about available sales and R&D positions

OptraSCAN Announces CLOUDPath LIMS as Part of its On-Demand Digital Pathology Solutions Suite on the Salesforce App Exchange the World’s Leading Enterprise Apps Marketplace

SUNNYVALE, CA — OptraSCAN, Inc. today announced the availability of CLOUDPathTM, a part of the On-Demand Digital Pathology Solutions Suite, to be launched on the Salesforce AppExchange, providing a highly affordable, secure, cloud-enabled LIMS app for customers using the Salesforce Health Cloud.

Built on the Salesforce App Cloud, CLOUDPathTM is currently available on the App Exchange. As part of the OptraSCAN On-Demand Digital Pathology solutions portfolio, CLOUDPath is a highly secure, HIPAA compliant, fully scalable cloud-enabled LIMS (laboratory information management system) offered through the OptraSCAN pay-per-usage subscription model—intended to make laboratory management more affordable. OptraSCAN’s complete On-Demand Solutions Suite includes a small-footprint, high and low throughput, frozen sections enabled WSI scanner OptraSCANTM, an integrated image viewer and image management system ImagePathTM with telepathology TELEPathTM, image analysis OptraASSAYSTM and CARDSTM (computer aided region detection system), as well as 10 TB of complimentary cloud storage and service.

LIMS on Salesforce AppExchange

CLOUDPath is one of the first LIMS applications to be offered on the Salesforce AppExchange for Digital Pathology with simple download installation allowing users to be up-and-running within the same day.

“Companies are looking to transform the way they connect with customers, partners and employees to thrive in the age of the customer,” said Todd Surdey, SVP, ISV Sales, Salesforce. “By leveraging the power of the Salesforce App Cloud, CLOUDPath provides customers with an efficient new way to manage laboratory operations in conjunction with customer data from Salesforce.” “OptraSCAN’s CLOUDPath LIMS is one of our On-Demand Digital Pathology solutions geared towards a pathologist of any use case. Through the On-Demand model, OptraSCAN is able to lower costs of digital transformation for the benefit of pathologists and humankind, helping to enable increased precision through objective pathology analysis,” says founder and CEO Abhi Gholap.

High Quality LIMS—Simple Integration

CLOUDPath brings together the Physician, Technician, Pathologist and Patient view using a HL7 interface that seamlessly integrates to other information systems. Case data including pathology images can be imported into the LIMS, and Report Wizards embed patient pathology images into patient reports. This modification now enables the ability for Salesforce to handle images, including pathological images.

Take a tour of CLOUDPath on the SalesForce AppExchange, try it out for free for 15-days or watch a quick tutorial here.

About Salesforce AppExchange

Salesforce AppExchange is the world’s leading enterprise apps marketplace that empowers companies to sell, service, market and engage in entirely new ways. With 3,000 partner apps and more than 3.8 million customer installs, it is the most comprehensive source of cloud, mobile, social, IoT and data science technologies for businesses.

Salesforce, AppExchange and others are among the trademarks of, Inc.

About OptraSCAN, Inc.

OptraSCANTM ( for research-use-only, is the first On-Demand Digital Pathology system to provide a comprehensive, affordable end-to-end Digital Pathology solution for both low volume, high-throughput and frozen sections users. OptraSCANTM serves as a perfect tool for the transition from conventional microscopy to Digital Pathology for the effective acquisition of Whole Slide images, viewing, sharing, analysis and management of digital slides and associated metadata. The On-Demand solutions include a small-footprint, high and low throughput WSI scanner OptraSCANTM, an integrated image viewer and image management system ImagePathTM and telepathology TELEPathTM, image analysis OptraASSAYSTM and CARDSTM (computer aided region detection system), as well as 10 TB of complimentary cloud storage. Focused on delivering fully integrated Digital Pathology solutions that maximize quality, efficiency and throughput of its customer’s pathology lab (at minimized cost), paired with a complimentary Whole Slide image scanner and viewer—OptraSCAN provides a complete Whole Slide Image solution system via an On-Demand pay-per-use program. Follow OptraSCAN on Linkedin and Twitter.

Source: OptraSCAN

Mikroscan Collaborates With Johns Hopkins University School of Medicine to Develop Next-Generation Image Analysis Tools

Research agreement creates academic collaboration to develop deep learning tools for rapid onsite evaluation of adequacy (ROSEA)

mikroscan-logo-mainDecember 1, 2016 Mikroscan Technologies, maker of affordable desktop real-time telemicroscopy solutions, announces a research agreement with Johns Hopkins University School of Medicine to develop automated cytology analysis tools for ROSEA. The research will be led by Johns Hopkins University School of Medicine’s Assistant Professor of Pathology, Matthew T. Olson, MD. The agreement leverages Mikroscan’s SL5 telemicroscopy ability to view pathology images in real time, through the use of a live, robotic microscope, as well as Professor Olson’s extensive knowledge of cytology-based image algorithm development. The goal of the project is to reduce the incidence of repeat procedures that are burdensome to patients and expensive for hospitals.

“Rapid onsite evaluation of adequacy presents many challenges for pathologists”, said Mikroscan’s President, Martin Stuart, PhD. “Pathologists are often required to travel to remote locations for an assessment of adequacy that takes just a few seconds to complete. Combining the SL5’s telemicroscopy and live robotic microscope capability with cytology-based image analysis can assist in more efficient use of a pathologist’s time and create more productive and cost-effective practices.”

“Dr. Olson’s current work focuses on the complementarity of emerging technologies with challenges in the diagnostic process of cytologic specimens and small biopsies. Defining these challenges in the diagnostic process have recently led him to lead investigations into inter-observer reproducibility, the outcome of paucicellular cytologic specimens, and nomenclature standardization in the new Paris System for reporting urinary cytology.”

About Mikroscan Technologies, Inc. 

Mikroscan provides affordable desktop telemicroscopy and digital pathology* solutions designed to promote the practice of pathology from a distance. Our mission is to distribute pathology expertise on demand, regardless of location, and in the process reduce healthcare costs and improve patient care. For more information about Mikroscan, please visit

*”For Research Use Only. Not for use in diagnostic procedures.”

Source: Mikroscan

House Passes 21st Century Cures Act

USA Today (11/30, Shesgreen, 5.28M) reports that the House on Wednesday approved the 21st Century Cures Act, a “sweeping health policy bill…aimed at sparking medical innovation, strengthening mental health services, and curbing the nation’s deadly opioid epidemic.” The legislation “cleared the House with broad bipartisan support, 392-to-26.”

The New York Times (11/30, Steinhauer, Tavernise, Subscription Publication, 13.9M) says Senate passage “appears likely” next week, “even though Senator Elizabeth Warren, Democrat of Massachusetts, has taken to the floor twice to criticize the bill as a windfall for drug companies, with too few safety provisions.”

Medscape (11/30, Lowes, 339K) reports the additional funding is “one of the most applauded parts of Cures.” The funds will be distributed for NIH “research projects that include the Cancer Moonshot, the Precision Medicine Initiative,” the “Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, and regenerative medicine using stem cells.” Group “such as the American Society of Clinical Oncology like increased funding for the Cancer Moonshot, while neurologists like more money for the BRAIN Initiative.”

Source: ASCO